

Figure 2. INC inhibits migration and invasion activities of SUIT-2. (A) For migration activity, SUIT-2 (2.5×10^5) cells were incubated with the indicated concentration of INC for 24 h and allowed to migrate through non-coated transwell plates for 24 h. (B) For invasion activity, SUIT-2 (2.5×10^5) cells were incubated with the indicated concentration of INC for 24 h and allowed to migrate through Matrigel-coated (8.7 mg/ml) transwell plates for 24 h. In either case, after fixing and staining with Diff-Quik stain solution, the number of migrated or invaded cells was counted. Bar, 200 μ m. N=3 for each experiment. * $p < 0.05$, ** $p < 0.01$ vs. untreated cells.




Figure 3. The activation of Rho by LPA is suppressed by INC, and restored by the addition of GGOH in SUIT-2. SUIT-2 cells were cultured under serum-free conditions with or without the various agents indicated for 24 h. After incubation, the cells were stimulated with LPA. The cell lysates were incubated with Rhotekin-RBD beads. Bound Rho proteins were detected by Western blotting using a monoclonal antibody against RhoA (upper panel). Western blotting of the total amount of Rho in cell lysates (lower panel) was performed for comparison with Rho activity (level of GTP-bound Rho) in the same lysates. Blots are representative of three experiments. Relative amounts of active Rho normalized with the amounts of total Rho were determined by densitometric scanning and shown. The concentrations of agents that were used are as follows: LPA 2.2 μ M; INC 30 μ M; GGOH 30 μ M.

we used a pancreatic cancer model with i.p. carcinomatosis in nude mice. We started the administration of INC on the day of cancer cell inoculation. Preliminary experiments revealed that tumor-bearing mice began to exhibit abdominal swelling with ascites ~2.5 weeks after cancer cell inoculation and died from cachexia after the 5th week without any treatment. Therefore, we sacrificed and examined mice 4 weeks after cancer cell inoculation. At the autopsy examination, tumors were found on the surface of the peritoneum, diaphragm, intestines, liver, spleen, pancreas, and kidney, with massive ascites in the control group. The extent of tumor burden varied among the different treatment groups (Fig. 4A). Mean tumor weight in the peritoneum of the untreated group was 1.58 ± 0.29 g, and was significantly reduced by ~40% in the group given 1 mg/kg/d (0.63 ± 0.14 g; $p < 0.05$), by ~40% in the group given 2 mg/kg/d (0.63 ± 0.15 g; $p < 0.05$), and by ~39% in the group given 3 mg/kg/d (0.62 ± 0.13 g; $p < 0.05$) (Fig. 4B). Fig. 4C shows the effects of INC treatment

on ascites formation. The inhibitory effect of INC on ascites formation was dose-dependent. The mean volume of ascites in the untreated group was 2.91 ± 0.26 ml; and was significantly reduced by ~49% in the group given 1 mg/kg/d (1.42 ± 0.40 ml; $p < 0.05$). Strikingly, INC treatment at 2 mg/kg/d and 3 mg/kg/d reduced ascites formation by ~23% (0.67 ± 0.49 ml; $p < 0.01$) and by ~21% (0.60 ± 0.28 ml; $p < 0.01$), respectively. The concentration of CA19-9, which was expressed from SUIT-2 (20), was examined in the serum collected from the left heart ventricle (Fig. 4D). The effect of INC treatment on the mean concentrations of CA19-9 was dose-dependent, although this did not reach statistical significance. Fig. 4E shows the histological appearance of the tumor nest formed after dissemination in the peritoneum from the untreated group. It shows how the tumor severely invaded into the peritoneum.

Discussion

Pancreatic cancer remains one of the most difficult malignancies to treat. Even patients who are eligible for curative surgical resection gain only moderate benefits. Furthermore, the lack of effective chemotherapeutic and targeted agents highlights the urgent need to better understand pancreatic cancer biology in order to guide the development of novel treatment strategies. During the progression of pancreatic carcinomas, cancer cells released from the surface of the tumor can adhere to and invade tissues and organs in the peritoneal cavity. Consequently, the poor outcome is, at least in part, due to peritoneal dissemination caused by the aggressive migration activity of pancreatic cancer cells (21,22). To undergo peritoneal dissemination, pancreatic cancer cells need to detach from the primary tumor, attach to the cell-extracellular matrix of other tissues, and migrate into the stroma. Once cancer cells migrate into the stroma, angiogenesis occurs from pre-existing capillaries or venules. Currently available anticancer drugs, even if they are very effective at killing cancer cells, can be used only at limited concentrations because of their toxicity to normal cells. Accordingly, it is worthwhile looking for drugs that inhibit the progression of pancreatic cancer affecting these properties, in addition to cell proliferation.




Figure 4. INC inhibits intraperitoneal dissemination in an *in vivo* pancreatic cancer model. (A) A SUI-2 cell suspension ($1 \times 10^6/200 \mu\text{l}$ mouse) was injected i.p. into nude mice and treated with the indicated amounts of INC everyday. Mice were sacrificed at 28 days after implantation and ascites, peritoneum, and blood sera were collected. The volumes of ascites (B), the weights of tumors disseminated on the peritoneum (C) and the concentrations of CA19-9 (D) were measured. N=6-10 (B and C); n=5 (D). * $p < 0.05$, ** $p < 0.01$ vs. untreated mice. (E) Histologic appearance of the tumor nest formed after dissemination in the peritoneum from a SUI-2-implanted nude mouse. Nude mice were injected i.p. with SUI-2 cells, sacrificed at 28 days after implantation, and the peritonea were collected. Tissue was fixed, sectioned, and stained with hematoxylin and eosin. T, tumor nest; P, peritoneum, Bar, $200 \mu\text{m}$.

Previous reports on the direct effects of N-BPs on cancer cells *in vitro* focused on cell viability and migration/invasion, and the effective concentrations of N-BPs were relatively high (14,16,23,24). According to these reports, the concentrations of alendronate, ibandronate, pamidronate, and zoledronate that induced apoptosis and inhibited invasion of breast, prostate, and ovarian cancer cells were $10\text{-}100 \mu\text{M}$. The present study also demonstrated that the effective concentrations of INC on the induction of apoptosis and the inhibition of migration/inva-

sion of pancreatic cancer cells were $10\text{-}100 \mu\text{M}$, whereas the concentration of INC that significantly inhibits osteoclast-like cell formation *in vitro* is $0.01\text{-}0.1 \mu\text{M}$, which is a clinically used concentration of INC (25). Although it is difficult to treat patients with N-BPs at concentrations of around $10\text{-}100 \mu\text{M}$ because of toxicity, clinical doses may be effective in the treatment of tumors for the following reasons. Tumor-associated macrophages (TAMs) play a pivotal role in tumor growth and metastasis by promoting tumor angiogenesis. Phagocytosis of N-BPs by TAMs

could lead to its depletion by apoptosis and elevate the concentration of N-BPs around the tumor (26).

We evaluated the ability of INC to inhibit the progression of disseminated pancreatic cancer *in vivo*. To accomplish this, we established an *in vivo* peritoneal dissemination model of pancreatic cancer in nude mice. In this model, cancer cells are injected i.p., and, as such, do not reproduce the early events of peritoneal dissemination, i.e. cancer development and detachment from a primary tumor. However, our previous results from a SUIT-2 orthotopic implantation model were nearly identical to those from the i.p. injection model (27), so we decided to use this simple and reproducible model in the present study. Similar to our *in vivo* results from pancreatic cancer cells, the N-BP alendronate, markedly inhibited tumor growth, invasiveness, and ascites formation of human ovarian cancer cells in a model of i.p. ovarian carcinomatosis (17). Such *in vivo* antitumor effects by N-BPs may be derived from the suppression of cancer cell proliferation by apoptosis as well as migration/invasion through the inhibition of molecules in the mevalonate pathway, especially Rho, in the target cancer cells.

This is the first report showing that an N-BP inhibited pancreatic cancer cell invasion to visceral organs *in vivo* and may provide the basis for a new therapy to control the dissemination of pancreatic cancer.

References

- Kleeff J, Michalski C, Friess H and Buchler MW: Pancreatic cancer: from bench to 5-year survival. *Pancreas* 33: 111-118, 2006.
- Ueno H, Kiyosawa K and Kaniwa N: Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? *Br J Cancer* 97: 145-151, 2007.
- Reni M, Cereda S and Galli L: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. *Cancer Lett* 256: 25-28, 2007.
- Xu Y, Shen Z, Wiper DW, *et al*: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. *JAMA* 280: 719-723, 1998.
- Baker DL, Morrison P, Miller B, *et al*: Plasma lysophosphatidic acid concentration and ovarian cancer. *JAMA* 287: 3081-3082, 2002.
- Yamada T, Sato K, Komachi M, *et al*: Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. *J Biol Chem* 279: 6595-6605, 2004.
- Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. *Nat Rev Cancer* 3: 582-591, 2003.
- Horwitz AR and Parsons JT: Cell migration - movin' on. *Science* 286: 1102-1103, 1999.
- Chrzanowska-Wodnicka M and Burridge K: Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. *J Cell Biol* 133: 1403-1415, 1996.
- Honn KV, Tang DG and Chen YQ: Platelets and cancer metastasis: more than an epiphenomenon. *Semin Thromb Hemost* 18: 392-415, 1992.
- Fisher JE, Rogers MJ, Halasy JM, *et al*: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation *in vitro*. *Proc Natl Acad Sci USA* 96: 133-138, 1999.
- Oxford G and Theodorescu D: Ras superfamily monomeric G proteins in carcinoma cell motility. *Cancer Lett* 189: 117-128, 2003.
- Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. *Adv Cancer Res* 84: 57-80, 2002.
- Virtanen SS, Vaananen HK, Harkonen PL and Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. *Cancer Res* 62: 2708-2714, 2002.
- Tassone P, Tagliaferri P, Viscomi C, *et al*: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells *in vitro*. *Br J Cancer* 88: 1971-1978, 2003.
- Sawada K, Morishige K, Tahara M, *et al*: Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. *Cancer Res* 62: 6015-6020, 2002.
- Hashimoto K, Morishige K, Sawada K, *et al*: Alendronate inhibits intraperitoneal dissemination in *in vivo* ovarian cancer model. *Cancer Res* 65: 540-545, 2005.
- Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. *J Immunol Methods* 70: 257-268, 1984.
- Ren XD, Kiosses WB and Schwartz MA: Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. *EMBO J* 18: 578-585, 1999.
- Iwamura T, Katsuki T and Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. *Jpn J Cancer Res* 78: 54-62, 1987.
- Vogel I, Kalthoff H, Henne-Bruns D and Kremer B: Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. *Pancreatol* 2: 79-88, 2002.
- Su D, Yamaguchi K and Tanaka M: The characteristics of disseminated tumor cells in pancreatic cancer: a black box needs to be explored. *Pancreatol* 5: 316-324, 2005.
- Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. *Br J Cancer* 82: 1459-1468, 2000.
- Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. *Cancer Res* 61: 4418-4424, 2001.
- Kitagawa Y, Hiraga T, Yura Y and Yoneda T: Suppression by incadronate of invasion and growth of A-375 human melanoma in mandible in nude mice. *Oncol Rep* 13: 211-216, 2005.
- Rogers TL and Holen I: Tumour macrophages as potential targets of bisphosphonates. *J Transl Med* 9: 177, 2011.
- Iguchi H, Mizumoto K, Shono M, Kono A and Takiguchi S: Pancreatic cancer-derived cultured cells: Genetic alterations and application to an experimental model of pancreatic cancer metastasis. In: *Culture of Human Tumor Cells*. Pfragner R and Freshney RI (eds.) John Wiley & Sons, Inc., Hoboken, NJ, pp81-96, 2004.

Upregulation of ERCCI and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer

H Baba^{*,1}, M Watanabe¹, H Okabe¹, Y Miyamoto¹, Y Sakamoto¹, Y Baba¹, M Iwatsuki¹, A Chikamoto¹ and T Beppu¹

¹Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1, Honjo, Kumamoto, 860-8556, Japan

BACKGROUND: The updated randomised phase 2/3 FIRIS study demonstrated the noninferiority of IRIS (irinotecan and S-1) to FOLFIRI (irinotecan, folinic acid, and 5-FU) for metastatic colorectal cancer. Meanwhile, in the subset analysis including patients who previously have undergone oxaliplatin-containing chemotherapy, the IRIS group showed longer survival than the FOLFIRI group. However, the molecular mechanism underlying this result is still unknown.

METHODS: The National Cancer Institute 60 (NCI60) cell line panel data were utilised to build the hypothesis. A total of 45 irinotecan-naïve metastatic colorectal cancer patients who had undergone hepatic resection were included for the validation study. The mRNA expressions of *excision repair cross-complementing group 1* (ERCCI), *dihydropyrimidine dehydrogenase* (DPD), and *topoisomerase-1* (TOP1) were evaluated by quantitative RT-PCR. The expressions of ERCCI and DPD were also evaluated by immunohistochemistry.

RESULTS: Sensitivity to oxaliplatin in 60 cell lines was significantly correlated with that of 5-FU. Resistant cells to oxaliplatin showed significantly higher ERCCI and DPD expression than sensitive cells. In validation study, ERCCI and DPD but not TOP1 expressions in cancer cells were significantly higher in FOLFOX (oxaliplatin, folinic acid, and 5-FU)-treated patients (N = 24) than nontreated patients (N = 21). The ERCCI and DPD protein expressions were also significantly higher in FOLFOX-treated patients.

CONCLUSION: The ERCCI and DPD expression levels at both mRNA and protein levels were significantly higher in patients with oxaliplatin as a first-line chemotherapy than those without oxaliplatin. The IRIS regimens with the DPD inhibitory fluoropyrimidine may show superior activity against DPD-high tumours (e.g., tumours treated with oxaliplatin) compared with FOLFIRI.

British Journal of Cancer (2012) **107**, 1950–1955. doi:10.1038/bjc.2012.502 www.bjancer.com

Published online 20 November 2012

© 2012 Cancer Research UK

Keywords: DPD; ERCCI; metastatic colorectal cancer; National Cancer Institute; oxaliplatin

The combination of fluorouracil (5-FU) and folinic acid with either oxaliplatin (FOLFOX-4 and FOLFOX-6 regimens) or irinotecan (FOLFIRI and AIO regimens) has been established as the standard first-line chemotherapy for metastatic colorectal cancer (O'Neil and Goldberg, 2008). Second-line therapy for patients whose disease progresses or recurs has been investigated in several clinical studies (Cunningham *et al*, 1998; Rougier *et al*, 1998, 2002; Tournigand *et al*, 2004). Patients who are initially treated with an oxaliplatin-based regimen tend to be offered an irinotecan-based regimen as second-line therapy and vice versa. However, the basic rationale for a sequential treatment strategy has been poorly studied.

An orally administered 5-FU pro-drug, S-1, is approved for the treatment of gastric cancer, colorectal cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and hepato biliary cancer in Japan, and for gastric cancer in Europe. S-1 consists of tegafur, a pro-drug of 5-FU, 5-chloro-2,4-dihydropyridine (CDHP), a dihydropyrimidine dehydrogenase (DPD) inhibitor maintaining the serum concentration of 5-FU, and potassium oxonate, an inhibitor of orotate phosphoribosyl transferase that reduces gastrointestinal toxicities.

We previously reported the updated results of the randomised phase 2/3 FIRIS study of 426 patients, which reconfirmed the noninferiority of IRIS (irinotecan/S-1) to FOLFIRI using progression-free survival (PFS) as the primary end point (Muro *et al*, 2010; Baba *et al*, 2011). Furthermore, we reported the pre-planned subset analysis that revealed that the median overall survival (OS) of the IRIS group in patients who previously underwent oxaliplatin-containing chemotherapy was significantly longer than that of the FOLFIRI group (adjusted HR = 0.755; 95% CI = 0.580–0.987) (Baba *et al*, 2011). Regarding this intriguing finding, Muro *et al* (2010) have speculated that S-1 might have some salvage effects in patients who previously received FOLFOX, containing oxaliplatin with bolus and infusional 5-FU. However, the mechanism underlying this interaction between the presence or absence of oxaliplatin and therapeutic effects in the FIRIS study remains unclear. The current retrospective study therefore investigated the molecular mechanisms for the superiority of IRIS to FOLFIRI in patients previously treated with oxaliplatin-based chemotherapy.

MATERIALS AND METHODS

NCI60 cell line data

The National Cancer Institute (NCI) database (<http://dtp.ccr.nih.gov>) containing data from 60 NCI60 cell lines was used. The

*Correspondence: Dr H Baba; E-mail: hdobaba@kumamoto-u.ac.jp

Received 13 June 2012; revised 8 October 2012; accepted 17 October 2012; published online 20 November 2012

source of cytotoxicity data for oxaliplatin (NSC266046), 5-FU (NSC19893), and DNA copy number. The GI_{50} , which is the concentration required to inhibit growth by 50%, was used as a parameter for cytotoxicity. The DNA microarray data for gene expression were downloaded from the Genomics and Bioinformatics group website (<http://discover.nci.nih.gov/>). Downloaded data were processed and loaded into GeneSpring software, version 7.3 (Agilent Technologies, Santa Clara, CA, USA). Correlations were calculated using Student's *t*-tests with JMP8.0 software (SAS Institute, Tokyo, Japan).

Patient characteristics

Irinotecan-naïve metastatic colorectal cancer patients, with Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, adequate organ function, and resectable liver metastases were enrolled in the study. Blocks from resected tumour specimens of liver metastatic lesions were available from 24 patients who preoperatively received the FOLFOX regimen, and 21 with no prior oxaliplatin-containing chemotherapy. All patients underwent hepatic resection for colorectal liver metastasis in the Department of Gastroenterological Surgery, Kumamoto University. The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients participating in the study. Approval of the protocol was obtained from an Independent Ethics Committee or the Institutional Review Board.

Microdissection

Representative haematoxylin and eosin-stained slides of formalin-fixed, paraffin-embedded (FFPE) blocks were reviewed by a pathologist to estimate tumour load per sample. Section slides of 10- μ m thickness were then stained with nuclear fast red (Sigma-Aldrich, St Louis, MO, USA) for manual microdissection. Malignant cells were selected under microscope magnification of $\times 5$ to $\times 10$ and dissected from the slide using a scalpel as described previously (Ceppi *et al*, 2006).

Isolation of RNA and cDNA synthesis

RNA isolation from tumour tissue isolated by manual microdissection and cDNA preparation steps were accomplished as described previously (Kuramochi *et al*, 2006), with a slight modification in the extraction step using RNeasy Mini Elute spin-columns (Qiagen, Chatsworth, GA, USA).

Quantitative real-time PCR

Gene expression levels of *excision repair cross-complementing group 1* (ERCC1), *DPD*, and *topoisomerase-1* (*TOP1*) were determined using TaqMan real-time PCR (Life Technologies, Foster City, CA, USA) as described previously (Kuramochi *et al*, 2006). β -Actin was used (*ACTB*) as an endogenous reference gene. All genes were run on all samples in triplicate. The detection of amplified cDNA results in a cycle threshold (Ct) value, which is inversely proportional to the amount of cDNA. Universal Mix RNAs (Stratagene, La Jolla, CA, USA) were used as control calibrators on each plate. The primer sequences for ERCC1, DPD, and ACTB were as previously described (Schneider *et al*, 2005). The Ct was the fractional cycle number at which the fluorescence generated by cleavage of the probe exceeded a fixed level above baseline. The relative amount of tissue target mRNA standardised against the amount of ACTB mRNA was expressed as follows: $-\Delta Ct = - (Ct_{(\text{target gene}-1)} - Ct_{(\beta\text{-actin})})$. The ratio of the number of target mRNA copies to the number of ACTB mRNA copies was then calculated as follows: $2^{-\Delta Ct} \times K$. Here, *K* is a constant (Livak and

Schmittgen, 2001). Contamination with genomic DNA was limited by amplifying nonreverse-transcribed RNA.

Immunohistochemistry

The FFPE tumour tissues were sliced into 4- μ m sections. The tissue specimens on the slide were then deparaffinised, and endogenous peroxidase was inactivated. For ERCC1 analysis, the slides were incubated at 4 °C overnight with the primary anti-ERCC1 monoclonal antibody (Clone D-10; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in a dilution of 1:100. For DPD analysis, the slides were incubated at 4 °C overnight with the primary anti-DPD monoclonal antibody (Clone OF-303, Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) in a dilution of 1:100. They were then reacted with a reagent containing horseradish peroxidase-labelled polymer-bound anti-mouse IgG (EnVision + system; Dako Japan Inc., Tokyo, Japan). The chromogenic substrate used for detection was DAB (3,3'-diaminobenzidine). Slides were counterstained with haematoxylin.

Immunohistochemical data analysis

The staining intensities of ERCC1 (Kim *et al*, 2009) and DPD (Okabe *et al*, 2000) were evaluated on a scale from 0 to 2+, as described previously with slight modifications. In brief, the positive reaction for both antibodies was scored into three grades, according to the intensity of the staining: 0, 1+, and 2+. The percentages of ERCC1- and DPD-positive cells were also scored into three categories: 0 (0%), 1 (1–49%), and 2 (50–100%). The product of the intensity by percentage scores was used as the final score. The immunostained specimens were independently evaluated by two blinded investigators (HB and HO). There was close agreement (>90%) between the two investigators; in the case of any disagreement, final grading was determined by consensus.

Statistical analysis

Categorical data analysis was conducted using the χ^2 test. The GI_{50} of 5-FU and ERCC1, mRNA level of ERCC1 and DPD, and immunohistochemical score of ERCC1 and DPD were compared using Spearman's correlation coefficient. Either the Student's *t*-test or Wilcoxon test was performed to determine the differences between groups. Results were considered statistically significant at $P < 0.05$. All statistical analyses were done with JMP version 8.01 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Data mining in the NCI database

The relationship between the cytotoxic effects of oxaliplatin (NSC266046) and 5-FU (NSC19893) in 60 NCI60 panel cell lines is shown in Figure 1A. The cytotoxic effects of oxaliplatin were significantly correlated with those of 5-FU (Spearman's Rho = 0.55, $P < 0.0001$).

For elucidating the underlying mechanism of the correlations between oxaliplatin and 5-FU cytotoxicities, gene expression levels as determined by cDNA microarray analysis were also examined. The NCI60 panel cell lines were arbitrarily classified as oxaliplatin-high-sensitive and oxaliplatin-low-sensitive cell lines according to their respective GI_{50} values. The oxaliplatin-high-sensitive cell lines were those with GI_{50} values within the 15th percentile, whereas the oxaliplatin-low-sensitive cell lines were above the 85th percentile. The remaining cell lines were classified as having intermediate sensitivity.

The Student's *t*-test revealed that the gene expression level of ERCC1 differed significantly ($P < 0.05$) between oxaliplatin-high-sensitive and oxaliplatin-low-sensitive cell lines, as shown in




Figure 1 Oxaliplatin-resistant cells showed high ERCC1 and DPD expression in *in silico* analysis. (A) Relationship between cytotoxic effects of oxaliplatin (NSC266046) and 5-FU (NSC19893) in 60 NCI60 panel cell lines. (B) Comparison of gene expression level, ERCC1 and DPD, or copy number between low sensitive cells and high sensitive cells to oxaliplatin. Data expressed as \log_2 (per chip normalised value $\times 500$). * $P < 0.05$.

Table 1 Patient characteristics

	Oxaliplatin free, n = 21 (%)	Oxaliplatin treated, n = 24 (%)	P-value ^a
Gender, no. (%)			0.344
Male	13 (62)	18 (75)	
Female	8 (38)	6 (25)	
Age			0.715
Median, years	62	63	
Range, years	45–75	28–82	
Tumour location (%)			0.974
Proximal colon	3 (14)	3 (13)	
Distal colon	9 (43)	11 (46)	
Rectum	9 (43)	10 (42)	
Differentiation (%)			0.873
Well	10 (48)	12 (50)	
Moderate	11 (52)	12 (50)	
Prior chemotherapy (%)			—
None	19 (90)	—	
5-FU/LV	1 (5)	—	
S1 + CPT-11 (IRIS)	1 (5)	—	
mFOLFOX6	—	20 (83)	
mFOLFOX6 + bevacizumab	—	4 (17)	

Abbreviations: 5-FU/LV = fluorouracil/leucovorin; IRIS = irinotecan and S-1; mFOLFOX6 = modified FOLFOX6. ^aThe P-values for gender were calculated using χ^2 test. The P-values for age, tumour location, differentiation, and prior chemotherapy were calculated using the Wilcoxon test.




Figure 2 The ERCC1 and DPD mRNAs upregulated in CRC patients with preoperative FOLFOX. (A) Typical slide for pathological diagnosis of FFPE tumour specimens (magnification $\times 2.4$). Sections, 5- μm -thick, stained with haematoxylin and eosin before microdissection (magnification $\times 50$). After staining with nuclear fast red, standard manual microdissection was performed (magnification $\times 50$). (B) Comparison of gene expression levels of ERCC1, DPD, and TOP1 in tumour cells with or without FOLFOX regimen before hepatectomy. * $P < 0.001$ for ERCC1 and $P = 0.005$ for DPD, respectively.

Figure 1B. Interestingly, the gene expression level of DPD also differed significantly ($P < 0.05$) between oxaliplatin-high-sensitive and oxaliplatin-low-sensitive cell lines (Figure 1B). Expression levels of ERCC1 and DPD in oxaliplatin-low-sensitive cell lines were 1.5 and 2.9 times higher than those in high-sensitive cell lines, respectively.

Lower sensitivity to oxaliplatin was associated with a parallel increase in ERCC1 and DPD expression. This finding may support that ERCC1 influences cytotoxicity after oxaliplatin treatment. Based on the findings of recent clinical translational studies (Lentz et al, 2005), ERCC1 was likely a predictive marker for colorectal cancer patients receiving oxaliplatin-containing therapy. Therefore, ERCC1 was investigated using clinical specimens from patients who had received a first-line chemotherapy with or without oxaliplatin.

Patient characteristics

Table 1 summarises patient characteristics. The median patient age at the time of liver dissection was 62 years (range, 28–82 years). There were no significant differences in clinicopathological factors such as gender, age, tumour location, or differentiation between patients with and without a prior oxaliplatin regimen.

Gene expression level of tumour specimens

The FFPE tumour specimens resected from liver metastasis were subjected to manual microdissection to ensure that only tumour cells were dissected (Figure 2A). As shown in Figure 2B, ERCC1 and DPD, but not TOP1, showed statistically significant higher expression in FOLFOX-treated patients ($n = 24$) compared with the nontreated group ($n = 21$). The mean expression level of ERCC1 and DPD in those receiving the FOLFOX regimen was 1.8 and 4.9 times higher, respectively, than in patients without any prior oxaliplatin-containing chemotherapy (ERCC1, $P < 0.0001$; DPD, $P = 0.005$). The expression level of ERCC1 was significantly correlated with that of DPD (Spearman's correlation coefficient = 0.519; $P = 0.0003$).

Immunohistochemical results

The RT-PCR analysis revealed higher expression of ERCC1 and DPD in FOLFOX-treated patients than nontreated patients. To confirm the protein expression levels of these genes, immunohistochemical examination was performed. The protein expression of ERCC1 (Figures 3A–C) was found in tumour cells, especially in the nucleus, whereas DPD protein expression was found in tumour cells and stromal cells (Figures 3D–F). For ERCC1, the mean (s.d.)

expression was 0.48 (0.68) in patients without FOLFOX and 1.42 (1.41) with FOLFOX (Figure 3G). For DPD, the mean (s.d.) expression was 0.14 (0.36) in patients without FOLFOX and 0.79 (1.02) with FOLFOX (Figure 3G). In accordance with RT-PCR results, immunohistochemical analysis showed that protein expression of both ERCC1 and DPD was significantly higher in FOLFOX-treated patients than nontreated patients ($P = 0.015$ and 0.0025, respectively; Figure 3G). Furthermore, a significant correlation between ERCC1 score and DPD score was shown (Spearman's correlation coefficient = 0.65; P -value < 0.0001).

DISCUSSION

In the present study, gene expression levels of ERCC1, which were extracted by the data mining process of NCI60 screening panel data, were significantly higher in recurrent metastatic cancer cells resected from patients who had received the FOLFOX regimen than from patients with no prior oxaliplatin-containing chemotherapy. In addition, the nucleoside catabolic gene DPD expression level also showed significant differences between patients with and without oxaliplatin as a first-line regimen. Given that the IRIS regimens with the DPD inhibitory fluoropyrimidine may show superior activity against DPD-high tumours compared with FOLFIRI, our




Figure 3 ERCC1 and DPD upregulated in CRC patients with preoperative FOLFOX. Representative pictures of ERCC1 and DPD in CRC patients. Cases of CRC showing weak (A), moderate (B), and strong (C) ERCC1 staining. Cases of CRC showing weak (D), moderate (E), and strong (F) DPD staining; bar = 50 μ m. (G) The expression scores of ERCC1 and DPD were compared between patients with FOLFOX and patients without FOLFOX using Wilcoxon test. * $P = 0.015$ for ERCC1 and $P = 0.0025$ for DPD, respectively.




Figure 4 Hypothesis of molecular mechanism of superiority in IRIS group for prior oxaliplatin-treated patients. This study demonstrated that oxaliplatin-resistant tumour cells showed high ERCCI and DPD, and thereby seemed to be sensitive to IRIS therapy.

findings may support the recent clinical result on the superiority of IRIS to FOLFIRI in patients previously treated with oxaliplatin-based chemotherapy.

Colon cancer is known to be a relatively heterogeneous tumour, and is characterised by a heterogenic pool of cells with distinct differentiation patterns. As an example, the *K-ras* mutation was thought to occur during early-stage tumour development; however, a recent study revealed intratumoural heterogeneity of *K-ras* mutations in 35–47% of primary colorectal carcinomas (Giaretti *et al*, 1996; Al-Mulla *et al*, 1998; Losi *et al*, 2005). Baldus *et al* (2010) also reported heterogeneity between primary tumours and lymph-node metastases in 31% (*K-ras*), 4% (*BRAF*), and 13% (*PIK3CA*) of cases. Watanabe *et al* (2011b) found intratumoural heterogeneity of *K-ras* mutations in laser-captured microdissected specimens with respect to discordant *K-ras* status between primary and metastatic colorectal tumours. Such genetic alterations, not only in *K-ras* but also in other genes, could result in intratumoural heterogeneous gene expression (Watanabe *et al*, 2011a). Recently, the concept that cancer might arise from a rare population of cells with stem cell-like properties has received support with regard to several solid tumours, including colorectal cancer (Barker *et al*, 2007; Dalerba *et al*, 2007; O'Brien *et al*, 2007; Ricci-Vitiani *et al*, 2007; Huang *et al*, 2009; Ricci-Vitiani *et al*, 2009; van der Flier *et al*, 2009). Considering the therapeutic implications of cancer stem cells, the failure of current standard therapies to eradicate tumours fully could be explained by assuming that colorectal cancer stem cells are able to survive treatments and achieve only a transitory clinical remission.

Based on our experimental results and knowledge of tumour cell biology, we propose the following hypothesis to explain why the IRIS regimen was superior to the FOLFIRI regimen for colorectal cancer patients who had been treated with oxaliplatin-based regimen. As shown in Figure 4, heterogeneous tumours were exposed to first-line oxaliplatin-containing therapy (mainly the mFOLFOX6 regimen for the FIRIS study, and partly mFOLFOX6 combined with bevacizumab). After the first-line treatment, oxaliplatin-sensitive tumour cells (i.e., *ERCCI* low; illustrated in blue in Figure 4) are killed and a small fraction of relatively oxaliplatin-resistant cells (i.e., *ERCCI* high; illustrated in yellow in

Figure 4) survive, which might include cancer stem cells. In NCI60 cell line data, *ERCCI* and *DPD* gene expression is confounding; surviving cells will exhibit high *DPD* gene expression. Consequently, failure of first-line treatment might result in the proliferation of oxaliplatin-resistant tumour cells, which exhibit high levels of *DPD* gene expression. Because the IRIS (S-1/irinotecan) regimen contains S1, the *DPD* inhibitory fluoropyrimidine, it will show superior activity to FOLFIRI (5-FU/LV/irinotecan, non-*DPD* inhibitory fluoropyrimidine) against *DPD*-high tumours. This hypothesis was originally proposed when the updated results of the FIRIS study were reported at the 2011 meeting of the American Society of Clinical Oncology (ASCO) (Baba *et al*, 2011). Molecular mechanisms explaining why *ERCCI* and *DPD* gene expressions seemed to be confounding each other in cancer cells remain unclear. Recently, methylation has been recognised as an epigenetic alteration that leads to gene silencing in human cancer (Estellar, 2003). The role of aberrant methylation of the *DPD* or *ERCCI* promoter as a potential common epigenetic regulatory mechanism in tumour cells remaining after oxaliplatin-based chemotherapy warrants investigation.

A limitation of the present study was the relatively small number of patients included. Nevertheless, the phenomenon identified might be useful in selecting second-line treatments for patients who would benefit the most, and in providing a rationale for selecting therapy. To confirm our hypothesis, the study should be confirmed using an independent cohort of patients. To our knowledge, this is the first report to demonstrate a basic rationale for second-line therapy against the failures of first-line therapy containing oxaliplatin in colorectal cancer patients.

ACKNOWLEDGEMENTS

Our study was supported by an unrestricted technical assistance from Taiho Pharmaceutical Co., Ltd, Japan. We thank Keisuke Miyake, Naomi Yokoyama, and Yuko Taniguchi for their technical support to this report. We also thank Takashi Kobunai for his helpful advice.

REFERENCES

- Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD (1998) Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. *J Pathol* 185: 130–138
- Baba H, Muro K, Yasui H, Shimada Y, Tsuji A (2011) Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC). *J Clin Oncol* 29: 2011 (Suppl; Abstract 3562)

- Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. *Clin Cancer Res* 16: 790-799
- Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegbarth A, Korving J, Begthel H, Peters PJ, Clevers H (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 449: 1003-1007
- Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV (2006) ERCCI and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. *Ann Oncol* 17: 1818-1825
- Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. *Lancet* 352: 1413-1418
- Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF (2007) Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci USA* 104: 10158-10163
- Estellar M (2003) Relevance of DNA methylation in the management of cancer. *Lancet Oncol* 4: 351-358
- Giarretti W, Monaco R, Pujic N, Rapallo A, Nigro S, Geido E (1996) Intratumor heterogeneity of K-ras 2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. *Am J Pathol* 149: 237-245
- Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* 69: 3382-3389
- Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK (2009) Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. *Br J Cancer* 100: 732-738
- Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV (2006) Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. *Clin Cancer Res* 12: 29-33
- Lentz F, Tran A, Rey E, Pons G, Treluyer JM (2005) Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. *Am J Pharmacogenomics* 5: 21-33
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408
- Losi L, Baisse B, Bouzourene H, Benhattar J (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. *Carcinogenesis* 26: 916-922
- Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). *Lancet Oncol* 11: 853-860
- O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 445: 106-110
- O'Neil BH, Goldberg RM (2008) Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. *Oncologist* 13: 1074-1083
- Okabe H, Arakawa K, Takechi T, Fukushima M (2000) Expression of recombinant human dihydropyrimidine dehydrogenase and its application to the preparation of anti-DPD antibodies for immunochemical detection. *Gan To Kagaku Ryoho* 27: 891-898
- Ricci-Vitiani L, Fabrizio E, Palio E, De Maria R (2009) Colon cancer stem cells. *J Mol Med (Berl)* 87: 1097-1104
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. *Nature* 445: 111-115
- Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, Hua A, Mery-Mignard D (2002) Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. *Ann Oncol* 13: 1558-1567
- Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. *Lancet* 352: 1407-1412
- Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV (2005) Downregulation of TS, DPD, ERCCI, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. *J Am Coll Surg* 200: 336-344
- Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 22: 229-237
- van der Flier LG, Haegbarth A, Stange DE, van de Wetering M, Clevers H (2009) OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. *Gastroenterology* 137: 15-17
- Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K (2011a) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. *Eur J Cancer* 47: 1946-1954
- Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K (2011b) Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. *Dis Colon Rectum* 54: 1170-1178

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma

K Hirashima^{1,2}, Y Baba^{1,2}, M Watanabe¹, R-I Karashima¹, N Sato¹, Y Imamura¹, Y Nagai¹, N Hayashi¹, K-I Iyama² and H Baba^{*,1}

¹Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan; ²Department of Surgical Pathology, Kumamoto University Hospital, 1-1-1 Honjo, Kumamoto 860-8556, Japan

BACKGROUND: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and homeostasis. The presence and prognostic significance of inappropriate mTOR activation have been reported for several cancers. Mammalian target of rapamycin inhibitors, such as everolimus (RAD001), are in development and show promise as anti-cancer drugs; however, the therapeutic effect of everolimus on oesophageal squamous cell carcinoma (OSCC) remains unknown.

METHODS: Phosphorylation of mTOR (p-mTOR) was evaluated in 167 resected OSCC tumours and 5 OSCC cell lines. The effects of everolimus on the OSCC cell lines TE4 and TE11 *in vitro* and alone or in combination with cisplatin on tumour growth *in vivo* were evaluated.

RESULTS: Mammalian target of rapamycin phosphorylation was detected in 116 tumours (69.5%) and all the 5 OSCC cell lines. Everolimus suppressed p-mTOR downstream pathways, inhibited proliferation and invasion, and induced apoptosis in both TE4 and TE11 cells. In a mouse xenograft model established with TE4 and TE11 cells, everolimus alone or in combination with cisplatin inhibited tumour growth.

CONCLUSION: The mTOR pathway was aberrantly activated in most OSCC tumours. Everolimus had a therapeutic effect both as a single agent and in combination with cisplatin. Everolimus could be a useful anti-cancer drug for patients with OSCC.

British Journal of Cancer (2012) **106**, 876–882. doi:10.1038/bjc.2012.36 www.bjcancer.com

Published online 14 February 2012

© 2012 Cancer Research UK

Keywords: everolimus; RAD001; mTOR; oesophageal squamous cell carcinoma; proliferation

Oesophageal squamous cell carcinoma (OSCC), the major histological type of oesophageal cancer in East Asian countries, is one of the most aggressive malignant tumours (Enzinger and Mayer, 2003). Despite the development of multimodal therapies, including surgery, chemotherapy, and radiotherapy, the prognosis remains poor even for patients who undergo complete carcinoma resection. The limited improvement in outcomes achieved by conventional therapies urges us to seek innovative strategies, especially those involving molecular targeting, for treating OSCC.

The mammalian target of rapamycin (mTOR) is a 289-kDa serine/threonine kinase involved in cellular growth and homeostasis (Bjornsti and Houghton, 2004; Abraham and Gibbons, 2007; Menon and Manning, 2008; Wouters and Koritzinsky, 2008). Mammalian target of rapamycin is activated by phosphorylation as a part of the phosphatidylinositol-3 kinase/AKT signalling pathway (Mita *et al*, 2003; Chan, 2004; Dancey, 2006) and in turn phosphorylates and activates eukaryotic translation factor 4E (eIF4E) and p70 ribosomal S6 kinase (p70S6 kinase), leading to the translation of proteins required for cell cycle progression (Hidalgo and Rowinsky, 2000; Panwalkar *et al*, 2004). The presence and prognostic significance of aberrant mTOR activation have been reported for several types of human carcinomas (Easton and Houghton, 2006; Herberger *et al*, 2007; Hou *et al*, 2007; Hudes,

2009; Hirashima *et al*, 2010). Our group previously showed an association between high phosphorylated mTOR (p-mTOR) expression and poor prognosis in 143 resected OSCC samples (Hirashima *et al*, 2010). Mammalian target of rapamycin has recently been recognised as an important and attractive target for anti-cancer therapy (Boulay *et al*, 2004; Bianco *et al*, 2006; Johnston, 2006; Antonarakis *et al*, 2010; Sparks and Guertin, 2010). Everolimus, an oral mTOR inhibitor, has shown particularly promising results in experimental studies, inhibiting tumour growth and displaying anti-angiogenic effects (Carmeliet and Jain, 2000; Bianco *et al*, 2008; Manegold *et al*, 2008; Lane *et al*, 2009). Combination therapy using everolimus and cisplatin has also been reported to be effective (Beuvink *et al*, 2005; Mabuchi *et al*, 2007; Hou *et al*, 2010; Ma *et al*, 2010). Many clinical trials using everolimus for several types of cancers are currently underway (Yee *et al*, 2006; Fouladi *et al*, 2007; Gridelli *et al*, 2007; Johnson *et al*, 2007; Awada *et al*, 2008; O'Donnell *et al*, 2008; Taberner *et al*, 2008; Tanaka *et al*, 2008; Yao *et al*, 2008; Wolpin *et al*, 2009). Everolimus has been already approved for the treatment of advanced renal cell carcinoma in patients whose disease has progressed during or after VEGF-targeted therapy (Coppin, 2010). Nonetheless, to our knowledge, no study has examined the therapeutic effect of everolimus on OSCC using *in vitro* and *in vivo* assays.

We therefore conducted this study with three main aims. First, we examined the importance of mTOR activation in OSCC by determining the overall prevalence of p-mTOR expression in OSCC

*Correspondence: Dr H Baba; E-mail: hdbaba@kumamoto-u.ac.jp
Revised 10 January 2012; accepted 11 January 2012; published online 14 February 2012

specimens and cell lines. Second, we evaluated the therapeutic effect of everolimus on OSCC cell lines by both *in vitro* and *in vivo* assays. Third, we specifically assessed the effect of everolimus in combination with cisplatin, which is one of the most frequently used chemotherapeutic drugs, on OSCC cells.

MATERIALS AND METHODS

Reagents and antibodies

Everolimus was provided by Novartis Pharma AG (Basel, Switzerland) and formulated at 2% (w/v) in a microemulsion vehicle. For *in vivo* analysis, everolimus was diluted to the appropriate concentration in double-distilled water just before administration by gavage. For *in vitro* analyses, everolimus was prepared in DMSO just before addition to cell cultures. Antibodies recognising mTOR, phospho-mTOR (Ser²⁴⁴⁸), p70s6k, phospho-p70s6k (Thr³⁸⁹), 4E-BP1, phospho-4E-BP1 (Thr⁷⁰), and β -actin were purchased from Cell Signaling Technology (Boston, MA, USA).

Patients

The present study involved 167 consecutive patients who underwent surgical resection of OSCC at the Kumamoto University Hospital from January 1996 to December 2007. None of these patients underwent endoscopic mucosal resection, palliative resection, preoperative chemotherapy, preoperative radiotherapy, or preoperative chemoradiotherapy. This study was approved by the Institute Review Board of the Graduate School of Medical Science, Kumamoto University (Approval number: 236; 2 August 2008).

Immunohistochemistry for p-mTOR

The method of immunohistochemical staining for p-mTOR was described previously (Hirashima *et al*, 2010). Of the 167 tumours, 51 showed no p-mTOR expression, 84 showed weak expression, and 32 showed strong expression. As the aim of the immunohistochemistry in this study was to evaluate the prevalence of p-mTOR expression in OSCC tissues, both weak and strong p-mTOR expression were defined as positive.

Cell culture

Oesophageal squamous cell carcinoma cell lines (TE series) were obtained from the Cell Resource Center for Biomedical Research, Tohoku University. Cell cultures were grown in the recommended medium with 10% foetal bovine serum and incubated in 5% CO₂ at 37 °C.

Western blot analysis

Cultured cells were harvested and lysed in lysis buffer (25 mM Tris-HCl (pH 7.4), 100 mM NaCl, 2 mM EDTA, 1% Triton X-100, leupeptin, 1 mM Na₃VO₄, and 1 mM PMSF) for 30 min. Lysates were centrifuged at 10 000 rpm for 5 min at 4 °C. Each protein sample (10 μ g) was mixed with 5 \times sample buffer containing 10% β -mercaptoethanol and boiled for 5 min. The total cellular protein extracts were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% gels for the examination of mTOR and p-mTOR, and on 12.5% gels for the examination of p70S6K, p-p70S6K, 4E-BP1, p-4E-BP1, and β -actin. The samples were then transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA), which were blocked overnight at 4 °C in 5% skim milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20. The membranes were probed overnight at 4 °C with each primary monoclonal antibody followed by incubation with peroxidase-conjugated anti-rat IgG antibody (1:1000) (Sigma,

St Louis, MO, USA). The targets were detected using an enhanced chemiluminescence (ECL) reagent (GE Healthcare, Piscataway, NJ, USA).

Cell proliferation analysis

The effect of everolimus on cell proliferation was evaluated using a water-soluble tetrazolium salt (WST-8; (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, monosodium salt) (Dojin Chemicals, Tokyo, Japan). TE4 and TE11 cells were cultured overnight in 96-well plates (3 \times 10³ cells per well). Cells were then treated for 48 h with everolimus (20 nM) or vehicle (control) and their viabilities were assessed. The number of surviving cells in each sample was determined from its absorbance at 450 nm (A₄₅₀).

Cell cycle analysis

The cell cycle distribution of TE4 and TE11 cells treated with everolimus (20 nM) or vehicle (control) for 48 h was analysed by flow cytometry using a BD FACSCalibur (BD Bioscience, San Jose, CA, USA) according to previously published methods (Del Bufalo *et al*, 2004; Milella *et al*, 2004).

Apoptosis analysis

TE4 and TE11 cells were treated with everolimus (20 nM) or vehicle (control) for 48 h and then apoptosis was assessed by flow cytometry using Annexin V-FITC (BD Bioscience) and propidium iodide (PI) staining according to previously published methods (Del Bufalo *et al*, 2004; Milella *et al*, 2004).

Invasion analysis

To evaluate the effect of everolimus on cell invasiveness, a Matrigel Invasion Chamber (BD Bioscience) was used according to the manufacturer's protocol. Matrigel-coated chambers containing 8 μ m pore-size filters were fitted into 24-well tissue culture plates. Briefly, cells of each type (TE4, 1.0 \times 10⁵ cells ml⁻¹; TE11, 5.0 \times 10⁵ cells ml⁻¹) were seeded into the Matrigel-coated chambers in RPMI-1640 medium with everolimus (20 nM) or vehicle (control) and incubated at 37 °C in 5% CO₂ for 24 h. The invasive cells on the bottom sides of the filters were stained using Torujin blue dye, and the numbers of cells in five randomly selected fields at \times 200 magnification were counted.

Subcutaneous xenograft model

All the procedures involving animals and their care were approved by the Animal Care and Use Committee of Kumamoto University. These procedures meet the standards required by the United Kingdom Coordinating Committee for Cancer Research (UKCCCR) guidelines (Workman *et al*, 2010). A subcutaneous xenograft model was used to assess the therapeutic effect on OSCC cells of everolimus either as a single agent or in combination with cisplatin, one of the chemotherapeutic drugs most frequently used for OSCC in the clinical setting. Six-week-old nude mice (BALB/c) (n = 24) were inoculated subcutaneously in the right or left flank with 5 \times 10⁶ TE4 cells and TE11 cells in 200 μ l of PBS. Some mice showed insufficient tumour growth and were therefore excluded from the study, leaving a total of 22 mice used for the single *in vivo* experiment. When the tumours reached approximately 50–70 mm³, the mice were randomised into four treatment groups (n = 5–6 mice per group). The first group was treated twice a week with placebo. The second group was treated twice a week with everolimus (5 mg kg⁻¹). The third group was treated every 2 weeks with cisplatin (3 mg kg⁻¹). The fourth group was treated twice a week with everolimus (5 ml kg⁻¹) and every 2 weeks with cisplatin




Figure 1 Immunostaining for p-mTOR. (A) Oesophageal squamous cell cancer cells positive for p-mTOR (white arrow). (B) Oesophageal squamous cell cancer cells negative for p-mTOR. (C) Western blot analysis of mTOR, p-mTOR, and β-actin levels in TE1, 4, 9, 11, and 13 cell lines.

(3 mg kg⁻¹) (Figure 4A). The validity of these everolimus and/or cisplatin protocols has been demonstrated in an ovarian cancer model. Everolimus was administered by oral gavage using an animal-feeding needle. Cisplatin was injected intraperitoneally. Body weight was measured every 3 days. Calliper measurements of the longest perpendicular tumour diameters were made weekly using a digital calliper, and tumour volumes were estimated using the following formula: $V = L \times W \times D \times \pi/6$, where V is the tumour volume, L the length, W the width, and D the depth (Mabuchi *et al*, 2007).

Statistical analysis

For the *in vitro* assays, including the cell proliferation assay, cell cycle ratio assay, apoptosis assay, and invasion assay, statistical analyses were performed using Mann-Whitney's *U*-test for unpaired samples. For the *in vivo* experiment, body weight and tumour volume were compared among placebo-, everolimus-, cisplatin-, and everolimus plus cisplatin-treated mice using the Wilcoxon exact test. Statistical analysis was performed with Stat View-J 5.0 software (Abacus Concepts, Inc., Berkeley, CA, USA). A two-sided significance level of $P < 0.05$ was used for all the statistical analyses.

RESULTS

Phosphorylated mTOR expression in OSCC specimens and cell lines

We assessed p-mTOR expression (i.e., mTOR activation) by immunohistochemistry. Of the 167 OSCC specimens, 116 (70%) were positive for p-mTOR expression (Figures 1A and B). The high percentage of p-mTOR-positive tumours supports the crucial role of mTOR activation in the pathogenesis of OSCC.

All five human OSCC cell lines (TE1, 4, 9, 11, and 13) examined in the current study showed p-mTOR expression *in vitro*; the expression level was highest in TE4 cells and lowest in TE11 cells (Figure 1C). Therefore, both TE4 and TE11 cells were used in the following experiments.

Everolimus attenuates phosphorylation of p70S6K and 4E-BP1 *in vitro*

The TE4 and TE11 cells were treated with different concentrations of everolimus (0 (vehicle control), 0.2, 2, and 20 nM) and the levels and phosphorylation of downstream mTOR targets, including p70S6k, p-p70S6k, 4E-BP1, p-4E-BP1, and β-actin (loading control), were evaluated by western blotting. Everolimus inhibited phosphorylation of p70S6k and 4E-BP1 (decreased levels of p-p70S6k and p-4E-BP1) in TE4 cells in a dose-dependent manner (Figure 2). In TE11 cells, 20 nM everolimus was sufficient to block phosphorylation of p70S6k and 4E-BP1 (Figure 2). Therefore, TE4 and TE11 cell lines were treated with 20 nM everolimus in the




Figure 2 Western blot analysis for p70S6k, p-p70S6k, 4E-BP1 p-4E-BP1, and β-actin protein levels in TE4 and TE11 cells treated with (at indicated concentrations) or without everolimus.

following assays (e.g., the *in vitro* proliferation, cell cycle, apoptosis, and invasion assays).

Therapeutic effect of everolimus on OSCC cell lines *in vitro*

Everolimus (20 nM) treatment for 48 h significantly inhibited the proliferation of both TE4 and TE11 cells (Figure 3A). In order to clarify the effect of everolimus on the cell cycle, OSCC cells were treated with everolimus (20 nM) and then subjected to cell cycle analysis by flow cytometry. An accumulation of cells in the G₀/G₁ phase and a reduction in the S-phase fraction were observed in both TE4 and TE11 cells treated with everolimus (20 nM) for 48 h (Figure 3B). Everolimus (20 nM) also significantly increased the proportion of early apoptotic cells (Annexin V-FITC positive, PI negative) compared with that of vehicle-treated cells in both TE4 and TE11 cells treated for 48 h (Figure 3C), indicating that everolimus could induce early apoptosis in these cell lines. Western blot analysis utilising antibodies for Bad and PARP also showed the induction of apoptosis by everolimus (Supplementary Figure 1); everolimus (20 nM) increased the expression of Bad and cleaved PARP protein. Finally, we performed an *in vitro* invasion assay using Matrigel Invasion Chambers and found that everolimus (20 nM) significantly decreased the numbers of invading TE4 and TE11 cells compared with those of vehicle-treated cells (Figure 3D).

Everolimus inhibits tumour growth in a mouse subcutaneous xenograft model

The mean tumour volumes on day 36 in a mouse xenograft model established with TE4 cells were 1314 ± 134 , 311 ± 87 , 542 ± 161 , and




Figure 3 *In vitro* assay for confirming the anti-cancer activity of everolimus. **(A)** *In vitro* proliferation assay. Treatment with everolimus (20 nM) for 48 h decreased the proliferation ratios of both TE4 and TE11 cells compared with those of control vehicle-treated cells. * $P < 0.05$. **(B)** *In vitro* cell cycle assay. Treatment with everolimus (20 nM) increased the percentages of TE4 and TE11 cells in G_0/G_1 phase compared with those of control vehicle-treated cells. * $P < 0.05$. **(C)** *In vitro* cell apoptosis analysis. Induction of early apoptosis in TE4 and TE11 cells by everolimus is shown (lower right part; Annexin V-FITC-positive, PI-negative). **(D)** *In vitro* invasion assay. Everolimus (20 nM) decreased the numbers of invading TE4 and TE11 cells compared with those of control vehicle-treated cells ($\times 200$ magnification, five fields). * $P < 0.05$.

Table 1 Effect of everolimus on tumour development of TE4 cell lines

Treatment	Number of mice	Mean tumour volume (mm ³)	% Effect of tumour reduction
Placebo	6	1314 ± 134	100
Everolimus	5	311 ± 87* [†]	23
Cisplatin	5	542 ± 161*	41
Everolimus+cisplatin	6	159 ± 21* [†]	12

*Significantly different from the placebo group ($P < 0.05$). [†]Significantly different from the cisplatin group ($P < 0.05$). [‡]Significantly different from the everolimus group ($P < 0.05$).

159 ± 21 mm³ in mice treated with placebo, everolimus, cisplatin, and everolimus plus cisplatin, respectively (Table 1, Figure 4B). Treatment with everolimus or cisplatin alone decreased the

tumour burdens by 83% and 68%, respectively, compared with that of placebo-treated mice (Figure 4C), indicating that everolimus used as a single agent has marked anti-tumour activity. Moreover, treatment with cisplatin plus everolimus decreased the tumour burden by 92% (Figure 4C), suggesting that the use of everolimus and cisplatin as a combination therapy might be promising. Similar results were obtained for TE11 cells (Supplementary Figure 2).

The weight changes of the mice over the course of the treatments did not differ significantly among the four groups, as shown in Supplementary Figure 3. In addition, we confirmed histologically that there were no differences in the levels of injury to the organs, including liver, kidney, pancreas, lung, intestine, and skin, among these four groups (Supplementary Figure 4). We continued to follow these mice for 2 months. Although all of the mice in the placebo group died within 2 months, no mouse in any of the other three groups died during this period.




Figure 4 *In vivo* assay for confirming the anti-cancer activity of everolimus utilising a mouse xenograft model established with TE4 cells. (A) Treatment schedules for the four treatment groups (placebo, everolimus, cisplatin, and everolimus plus cisplatin). (B) Tumour volume in the four treatment groups (placebo, everolimus, cisplatin, and everolimus plus cisplatin) after the 5-week course of treatment. (C) Growth of tumour volume in the four treatment groups.

DISCUSSION

Mammalian target of rapamycin is a key regulator of cell growth and proliferation and as such is regarded as a promising target for anti-cancer therapy (Kapoor, 2009; Scott *et al*, 2009). In this study, we made three intriguing findings. First, most OSCC tumours were positive for p-mTOR expression, supporting a role for mTOR activation in the pathogenesis of OSCC. Second, everolimus, an oral mTOR inhibitor, had a therapeutic effect on OSCC cell lines *in vitro*. Third, combination therapy with everolimus and cisplatin showed an additive effect on OSCC cells *in vivo*. Our findings certainly suggest that everolimus could be useful as an anti-cancer drug for patients with OSCC.

Previous studies have shown the importance of mTOR activation in OSCC specimens: Boone *et al*, (2008) detected activated mTOR in 25% of patients with OSCC, a subset of patients that might potentially benefit from mTOR-inhibiting therapy. Yoshioka *et al*, (2008) demonstrated that 48% of OSCC tumours showed high levels of p-mTOR phosphorylation. In the current study utilising 167 OSCC samples, about 70% of the OSCC tumours showed p-mTOR (i.e., mTOR activation). This discrepancy might be due to a difference in the method used to evaluate mTOR phosphorylation or in the cutoff for p-mTOR positivity. Nonetheless, these two previous studies and the current study certainly support the hypotheses that mTOR activation is important in the pathogenesis of OSCC and that mTOR inhibitors might be useful for OSCC treatment.

Everolimus, an orally bioavailable derivative of rapamycin, is a promising drug for cancer therapy. However, to our knowledge, no previous study has utilised *in vitro* and *in vivo* models to evaluate the therapeutic efficacy of everolimus. First, we demonstrated that everolimus suppressed down-stream signalling (i.e., phosphorylation of p70s6 kinase and 4E-BP1) and significantly inhibited cell proliferation and invasion of mTOR-activated OSCC cell lines *in vitro*. Second, we showed that inhibition of mTOR signalling by everolimus induced G₀/G₁ arrest and apoptosis, suggesting that everolimus might inhibit anti-apoptotic or survival signalling in OSCC cell lines. Third, we found that treatment with everolimus significantly inhibited tumour growth *in vivo*. Taken together, these results indicate that everolimus as a single agent could have significant anti-tumour efficacy against OSCC cells.

The effects of everolimus were more prominent in TE11 cells (p-mTOR-low) than in TE4 cells (p-mTOR-high). The malignant characteristics of OSCC cells are likely acquired not only through the mTOR signalling pathway but also through a wide variety of other signalling pathways. Although the activation level of the mTOR pathway was lower in TE11 cells than in TE4 cells, TE11 cells might depend more heavily on the mTOR pathway for their malignant behaviour. On the other hand, although TE4 cells showed a high level of mTOR activation, they might rely more on the other signalling pathways than on the mTOR pathway. In this study, the mTOR pathway was activated in all five cell lines assessed. If we could obtain an OSCC cell line without mTOR activation, those cells might well be resistant to everolimus. Future studies are necessary to confirm our findings as well as to elucidate the biological mechanisms by which the mTOR activation level affects the therapeutic efficacy of everolimus.

Interestingly, we also found an additive effect of everolimus and cisplatin on OSCC cells in an *in vivo* model. A similar effect has been reported for other types of carcinomas. Beuvink *et al*, (2005) reported that everolimus could sensitise cells to cisplatin by inhibiting induction of p21 expression by p53. Ma *et al*, (2010) showed that everolimus exerts an additive-to-synergistic effect on cisplatin-induced growth inhibition in nasopharyngeal carcinoma. Unfortunately, our current experiment could show only an additive effect rather than a synergistic effect. We expect that additional experiments in the future might be able to show a synergistic effect. However, we were at least able to recognise that combining everolimus and cisplatin might be a useful therapeutic strategy. As cisplatin is one of the most important chemotherapeutic drugs for OSCC treatment, our finding may have significant clinical implications.

In conclusion, most OSCC tumours showed mTOR activation, suggesting that mTOR could be a promising target for anti-cancer therapy against OSCC. Everolimus had a therapeutic effect on OSCC cells both *in vitro* and *in vivo*, and combination therapy with everolimus and cisplatin showed an additive effect. Although further experimental studies are necessary to confirm our findings, the current study certainly provides further rationale for future clinical trials of everolimus (in combination with cisplatin) in OSCC patients.

ACKNOWLEDGEMENTS

This work was made possible by the provision of everolimus (RAD001) by Novartis Pharma AG (Basel, Switzerland). We thank Novartis Pharma AG for their kindness. We thank Dr Katsunori Imai and Keisuke Miyake for *in vitro* technical assistance, and Dr Satoshi Ida and Dr Hasta Holrad for *in vivo* technical assistance. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or NIH. The funders had no role in the

study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

REFERENCES

- Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. *Clin Cancer Res* 13: 3109–3114
- Antonarakis ES, Carducci MA, Eisenberger MA (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. *Cancer Lett* 291: 1–13
- Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, Steinsieffer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. *Eur J Cancer* 44: 84–91
- Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. *Cell* 120: 747–759
- Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. *Br J Cancer* 98: 923–930
- Bianco R, Melisi D, Ciardiello F, Tortora G (2006) Key cancer cell signal transduction pathways as therapeutic targets. *Eur J Cancer* 42: 290–294
- Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. *Nat Rev Cancer* 4: 335–348
- Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegeersberg R (2008) mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? *J Clin Pathol* 61: 909–913
- Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. *Cancer Res* 64: 252–261
- Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. *Nature* 407: 249–257
- Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. *Br J Cancer* 91: 1420–1424
- Coppin C (2010) Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. *Biologics* 4: 91–101
- Dancey JE (2006) Therapeutic targets: MTOR and related pathways. *Cancer Biol Ther* 5: 1065–1073
- Del Bufalo D, Trisciuglio D, Scarsella M, D'Amati G, Candiloro A, Iervolino A, Leonetti C, Zupi G (2004) Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. *Neoplasia* 6: 513–522
- Easton JB, Houghton PJ (2006) mTOR and cancer therapy. *Oncogene* 25: 6436–6446
- Enzinger PC, Mayer RJ (2003) Esophageal cancer. *N Engl J Med* 349: 2241–2252
- Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. *J Clin Oncol* 25: 4806–4812
- Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P, Di Maio M, Ciardiello F (2007) A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. *Clin Lung Cancer* 8: 568–571
- Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. *Clin Cancer Res* 13: 4795–4799
- Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. *Oncogene* 19: 6680–6686
- Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K, Baba H (2010) Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. *Ann Surg Oncol* 17: 2486–2493
- Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y (2007) An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. *Cancer Lett* 253: 236–248
- Hou G, Zhang Q, Wang L, Liu M, Wang J, Xue L (2010) mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. *Cancer Lett* 290: 248–254
- Hudes GR (2009) Targeting mTOR in renal cell carcinoma. *Cancer* 115: 2313–2320
- Johnson BE, Jackman D, Janne PA (2007) Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. *Clin Cancer Res* 13: s4628–s4631
- Johnston SR (2006) Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. *Clin Cancer Res* 12: 1061–1088
- Kapoor A (2009) Inhibition of mTOR in kidney cancer. *Curr Oncol* 16(Suppl 1): S33–S39
- Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T (2009) mTOR inhibitor RAD001 (everolimus) has anti-angiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. *Clin Cancer Res* 15: 1612–1622
- Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT (2010) The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. *Invest New Drugs* 28: 413–420
- Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. *Clin Cancer Res* 13: 4261–4270
- Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ (2008) Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. *Clin Cancer Res* 14: 892–900
- Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. *Oncogene* 27(Suppl 2): S43–S51
- Milella M, Trisciuglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G (2004) Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. *Clin Cancer Res* 10: 7747–7756
- Mita MM, Mita A, Rowinsky EK (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. *Cancer Biol Ther* 2: S169–S177

- O'Donnell A, Faivre S, Burris 3rd HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. *J Clin Oncol* 26: 1588–1595
- Panwalkar A, Verstovsek S, Giles FJ (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. *Cancer* 100: 657–666
- Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. *Nature* 459: 1085–1090
- Sparks CA, Guertin DA (2010) Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. *Oncogene* 29: 3733–3744
- Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebowitz D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. *J Clin Oncol* 26: 1603–1610
- Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. *J Clin Oncol* 26: 1596–1602
- Wolpin BM, Hezel AF, Abrams T, Blazskowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. *J Clin Oncol* 27: 193–198
- Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. *Br J Cancer* 102: 1555–1577
- Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. *Nat Rev Cancer* 8: 851–864
- Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. *J Clin Oncol* 26: 4311–4318
- Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. *Clin Cancer Res* 12: 5165–5173
- Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, Okada K, Matsuyama J, Makari Y, Sohma I, Takiguchi S, Fujiwara Y, Monden M (2008) The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. *Oncol Rep* 19: 1099–1107

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma

J Kurashige¹, M Watanabe¹, M Iwatsuki¹, K Kinoshita¹, S Saito¹, Y Hiyoshi¹, H Kamohara¹, Y Baba¹, K Mimori² and H Baba^{*,1}

¹Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan;

²Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan

BACKGROUND: F-box and WD repeat domain-containing 7 (FBXW7) is a cell cycle regulatory gene whose protein product ubiquitinates positive cell cycle regulators such as c-Myc, cyclin E, and c-Jun, thereby acting as a tumour-suppressor gene. This study focused on microRNA-223 (miR-223), which is a candidate regulator of FBXW7 mRNA. The aim of this study was to clarify the clinical significance of miR-223 and FBXW7 in oesophageal squamous cell carcinoma (ESCC) patients, and to elucidate the mechanism by which FBXW7 is regulated by miR-223.

METHODS: The expression levels of miR-223 and the expression of FBXW7 protein was examined using 109 resected specimens to determine the clinicopathological significance. We also investigated the role of miR-223 in the regulation of FBXW7 expression in ESCC cell lines in an *in vitro* analysis.

RESULTS: We found that miR-223 expression was significantly higher in cancerous tissues than in the corresponding normal tissues. There was a significant inverse relationship between the expression levels of miR-223 and FBXW7 protein. Moreover, patients with high miR-223 expression demonstrated a significantly poorer prognosis than those with low expression. On the basis of a series of gain-of-function and loss-of-function studies *in vitro*, we identified FBXW7 as a functional downstream target of miR-223.

CONCLUSION: Our present study indicates that high expression of miR-223 had a significant adverse impact on the survival of ESCC patients through repression of the function of FBXW7.

British Journal of Cancer (2012) 106, 182–188. doi:10.1038/bjc.2011.509 www.bjcancer.com

Published online 22 November 2011

© 2012 Cancer Research UK

Keywords: microRNA; FBXW7; ubiquitin ligase

F-box and WD repeat domain-containing 7 (FBXW7) is the substrate recognition component of an evolutionarily conserved SCF (complex of SKP1, CUL1, and F-box protein)-type ubiquitin ligase complexes, which has been well characterised and shown to have important roles in regulating the stability of multiple oncoprotein substrates, including cyclin E, c-Myc, Notch, c-Jun, mammalian target of rapamycin, and MCL1 (Nakayama and Nakayama, 2006; Mao *et al*, 2008; Welcker and Clurman, 2008; Inuzuka *et al*, 2011; Wertz *et al*, 2011). Therefore, the altered expression of FBXW7 is recognised to be one of the major causes of carcinogenesis or cancer development. We have previously revealed that loss of FBXW7 correlated with a poor prognosis in colon cancer (Iwatsuki *et al*, 2010). Similarly, low expression of FBXW7 has been reported to be significantly associated with poor prognoses in glioma (Bredel *et al*, 2005; Hagedorn *et al*, 2007), gastric cancer (Yokobori *et al*, 2009), and breast cancer (Ibusuki *et al*, 2011). However, significance of downregulation of this molecule in oesophageal squamous cell carcinoma (ESCC) remains unknown.

Recent studies have revealed that microRNAs (miRNA) can act as oncogenes or tumour suppressors during the development and

progression of cancers through sequence-specific binding to their mRNA targets (Ambros, 2004; Zamore and Haley, 2005; Meister, 2007). These miRNAs have an important role in a wide variety of complex biological processes, including cellular development and differentiation, but investigations have only begun to clarify their significance in carcinogenesis (Calin *et al*, 2004; Croce and Calin, 2005). Some researchers have noted that alterations in the miRNA expression profile strongly affect the progression of human tumours and the prognosis of the patients (Yanaihara *et al*, 2006; Bloomston *et al*, 2007; Schetter *et al*, 2008; Ueda *et al*, 2010). Although our previous study revealed that miR-21 is significantly overexpressed in ESCC (Hiyoshi *et al*, 2009), there have been few reports concerning the miRNA profiles in ESCC.

It was recently reported that microRNA-223 (miR-223) targets the FBXW7 mRNA 3'-untranslated region, and that overexpression of miR-223 significantly reduces FBXW7 mRNA levels, increases endogenous cyclin E protein and activity levels, and increases genomic instability (Xu *et al*, 2010). Nevertheless, to our knowledge, no study has been reported on the relationship between the expression levels of miR-223 and FBXW7 in clinical samples of solid tumours. However, no correlation between miR-223 and FBXW7 has yet been elucidated in ESCC.

In the present study, we examined the correlation between the expression levels of miR-223 and immunohistochemical staining for the FBXW7 protein in 109 consecutive ESCC samples, and we

*Correspondence: Dr H Baba; E-mail: hdobaba@kumamoto-u.ac.jp
 Revised 29 September 2011; accepted 28 October 2011; published online 22 November 2011

also investigated the prognostic significance of the expression of miR-223. Moreover, we identified *FBXW7* as a functional downstream target of miR-223 *in vitro*.

PATIENTS AND METHODS

Patients and tissue samples

Primary ESCC tissue samples and samples of matched normal oesophageal epithelium were obtained from 109 patients who underwent oesophageal resection without preoperative treatment in the Department of Gastroenterological Surgery, Kumamoto University Hospital from 2000 to 2007. Written informed consent was obtained from all patients. The clinicopathological characteristics, including age, gender, pathology, differentiation, and tumour-node metastasis classification were available for all patients. Survival was measured from the time of oesophageal resection and death was the endpoint. The patient prognoses were examined in March 2011. The median observation time for survival was 31 months and it ranged from 1 to 132 months. The study was approved by the medical ethics committee of Kumamoto University.

ESCC cell lines

The human ESCC cell lines TE1, TE4, TE6, TE8, TE9, TE10, TE14, and TE15 were provided by the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University, Japan. All cells were grown in RPMI 1640 (Cambrex, East Rutherford, NJ, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA), 2 mmol l⁻¹ glutamine, 100 units of penicillin per ml, and 100 µg of streptomycin per ml (Cambrex), and were incubated at 37°C in a humidified chamber supplemented with 5% CO₂.

miRNA isolation

The miRNAs were extracted from formalin-fixed, paraffin-embedded oesophageal tissues using a RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Ambion, Austin, TX, USA), according to the manufacturer's instructions. The purity and concentration of all RNA samples were evaluated by their absorbance ratio at 260/280 nm determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA).

Quantitative real-time reverse transcription-PCR (qRT-PCR)

The expression levels of miR-223 were determined by TaqMan qRT-PCR using TaqMan microRNA assay kits (Ambion, USA) according to the manufacturer's protocols, as described previously (Hiyoshi *et al*, 2009). The miR-223 expression was normalised to that of RNU6B, a small nuclear RNA. The expression levels of *FBXW7* were determined using primers and probes that were designed using the Universal Probe Library (Roche Diagnostics, Mannheim, Germany) following the manufacturer's recommendations. The primer sequences used for real-time PCR were as follows: *FBXW7* forward 5'-AAAGAGTTGTAGCGGTTCTCG-3', reverse 5'-CCACATGGATACCATCAAACCTG-3' and universal probe #78; *18s rRNA* forward 5'-TGGAGGAGACGTTCCAGTGT-3', reverse 5'-GATCTGTCCAGGCAGTCCTT-3' and universal probe #17. All qRT-PCR reactions were run using a LightCycler 480 System II (Roche Diagnostics, USA). The relative amounts of miR-223 and *FBXW7* were measured using the 2^{-ΔΔCT} method. All qRT-PCR reactions were performed in triplicate.

Immunohistochemical analysis

The immunohistochemical studies for *FBXW7*, c-Myc, and c-Jun were performed on formalin-fixed, paraffin-embedded surgical

sections obtained from 109 patients with ESCC. Tissue sections of 5 µm thickness were deparaffinized and pre-treated for antigen retrieval by autoclave heating in 10 mM sodium citrate buffer (pH 9.0) for 15 min. These sections were blocked for endogenous peroxidase activity with 3% H₂O₂ in methanol for 60 min and then washed in phosphate-buffered saline. The sections were incubated in primary mouse monoclonal anti-*FBXW7* (1:100, Abnova Corporation, Taipei, Taiwan), mouse monoclonal anti-c-Myc (sc-40, 1:100, Santa Cruz Biotechnology, Fremont, CA, USA), or rabbit polyclonal anti-c-Jun (sc-1694, 1:50, Santa Cruz Biotechnology) antibody. Tissue sections were immunohistochemically stained using ENVISION reagents (ENVISION+ Dual Link System-HRP, Dako Cytomation, Glostrup, Denmark). All sections were counterstained with haematoxylin. The staining assessment was independently carried out by two authors (JK and YB) without any information about the patients' clinicopathological characteristics or prognosis.

Transfection of miRNA

The cells were transfected with 20 nM Pre-miR miRNA Precursor Molecule pre-223 (pre-miR-223) and 100 nM anti-miR miRNA inhibitor anti-223 (anti-miR-223) (Applied Biosystems) using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. The specificity of the transfection was verified using the Pre-miR miRNA Precursor Molecule Negative Control #1 (control pre-miR) and Anti-miR miRNA Inhibitors Negative Control #1 (control anti-miR) (Applied Biosystems). The expression levels of miR-223 and *FBXW7* were quantified 72 h after transfection, and the cells were used for a western blot analysis.

Western blot analysis

To isolate the proteins, cells harvested from 6-well plates were washed once in phosphate-buffered saline and lysed in lysis buffer (Tris-HCl (pH 7.4) 25 mmol l⁻¹, NaCl 100 mmol l⁻¹, EDTA 2 mmol l⁻¹, Triton X 1%, with 10 µg ml⁻¹ aprotinin, 10 µg ml⁻¹ leupeptin, and 1 mmol l⁻¹ Na₃VO₄, 1 mmol l⁻¹ phenylmethylsulfonyl fluoride). Each protein sample (15 µg) was resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred onto a polyvinylidene difluoride membrane, and incubated with a monoclonal antibody against c-Myc (sc-40, 1:500, Santa Cruz Biotechnology), c-Jun (sc-1694, 1:500, Santa Cruz Biotechnology) or β-actin (1:2000; Sigma-Aldrich). The signals were detected by incubation with secondary antibodies labelled using the ECL Detection System (GE Healthcare, Little Chalfont, UK).

Statistical analysis

All experiments were repeated at least three times. Continuous variables were expressed as the means ± s.d. The relationship between the expression of miR-223, the *FBXW7* protein, and the patient clinicopathological characteristics was analysed using Student's *t*-test or a χ²-analysis. The overall survival curves were plotted according to the Kaplan-Meier method, and the generalised log-rank test was applied to compare the survival curves. The findings were considered to be significant at a *P*-value < 0.05. All statistical analyses were performed using the SPSS v. 13.0 software program (SPSS, Inc., Chicago, IL, USA).

RESULTS

Clinicopathological significance of miR-223 in ESCC patients

The expression levels of miR-223 were examined in 109 ESCC clinical samples using qRT-PCR, with quantified values used to




Figure 1 The correlation between the expression of miR-223 and the FBXW7 protein in ESCC patients. **(A)** The expression level of miR-223 in tumour tissue specimens was significantly higher than that in non-tumour tissues ($P < 0.001$). **(B)** To evaluate the expression of FBXW7, the complete H score was semiquantitatively calculated (0–300). The relationship between miR-223 and FBXW7 in 109 clinical samples of ESCC indicated an inverse correlation (Pearson correlation, $r = -0.336$; $P < 0.01$).

calculate miR-223/U6B ratios. The mean expression levels of miR-223 in cancerous tissue specimens were significantly higher than those in non-cancerous tissues ($P < 0.001$; Figure 1A). We divided the 109 ESCC patients into two groups according to the ratio of their cancer/normal tissue expression levels of miR-223, as ≥ 1.0 or < 1.0 for the cancer/noncancerous tissues expression levels of miR-223. There were 74 cases (67.9%) in the high miR-223 group and 35 cases (32.1%) in the low miR-223 expression group. The association between the patient clinicopathological characteristics and miR-223 expression is summarised in Table 1. There were significant differences in gender ($P = 0.008$), tumour size ($P = 0.042$), and depth of tumour invasion ($P = 0.030$) between the groups.

The relationship between the expression of miR-223 and immunohistochemical staining for the FBXW7 protein in ESCC tissues

A fragment of the FBXW7 3'-untranslated region contained three putative miR-223 binding sites as determined by a computational analysis using miRNA target prediction programs such as

Table 1 The miR-223 expression and clinicopathological characteristics of the patients

Factors	Total (n = 109)	High (n = 74)	Low (n = 35)	P-value
Age (mean \pm s.d.)		66.0 \pm 9.5	65.0 \pm 8.4	0.967
Sex				0.008*
Male	90	66	24	
Female	19	8	11	
Histological grade				0.821
Well	42	28	14	
Moderate, poor, others	67	46	21	
Size				0.042*
< 40 mm (small)	50	29	21	
\geq 40 mm (large)	59	45	14	
Depth of tumor invasion				0.030*
T1	46	26	20	
T2/3	63	48	15	
Lymph node metastasis				0.707
Absent	47	31	16	
Present	62	43	19	
Lymphatic invasion				0.617
Absent	43	28	15	
Present	66	46	20	
Venous invasion				0.343
Absent	38	28	10	
Present	71	46	25	
Stage				0.072
I, II	78	49	29	
III, IV	31	25	6	
FBXW7				0.001*
Positive	39	16	23	
Negative	70	58	12	

Abbreviations: moderate = moderately differentiated; poor = poorly differentiated; well = well differentiated. Note: High miR-223 expression group ($n = 74$), miR223 (T)/miR223 (N) ≥ 1.0 ; low miR-223 expression group ($n = 35$), miR-223 (T)/miR-223 (N) < 1.0 . * $P < 0.05$.

Target Scan (<http://www.targetscan.org>) and miRanda (<http://www.microrna.org>) (Supplementary Figure 1).

We examined the FBXW7 protein expression level by an immunohistochemical analysis in the samples from ESCC patients. To evaluate the FBXW7 expression, the complete H score was semiquantitatively calculated by summing the products of the percentage of cells stained at a given staining intensity (0–100) and the staining intensity score (0, none; 1, weak; 2, moderate; and 3, intense). We found an inverse correlation between the expression levels of miR-223 and FBXW7 in 109 clinical samples of ESCC. High levels of miR-223 were associated with low FBXW7 expression (Pearson correlation, $r = -0.336$; $P < 0.01$; Figure 1B).

The prognostic significance of miR-223 and FBXW7 in ESCC

An analysis of 5-year overall survival demonstrated that the high miR-223 expression group had a significantly poorer prognosis than the low expression group ($P = 0.034$; Figure 2A). Similarly, the negative FBXW7 group had a significantly poorer prognosis of 5-year overall survival than the positive group ($P = 0.023$; Figure 2B). In a univariate Cox regression analysis, compared with the low miR-223 expression group, the high miR-223 expression group experienced a significantly higher overall mortality (hazard

ratio 2.272; 95% confidence interval, 1.099–4.695; $P=0.027$; Table 2). In the univariate analysis, other significant prognostic factors for cancer-specific survival included lymph node metastasis ($P=0.008$), lymphatic invasion ($P=0.002$), and FBXW7 expression ($P=0.023$). In a multivariate Cox regression analysis for overall survival, including age at operation, N status, venous invasion, and miR-223 expression, high miR-223 expression was revealed to be an independent prognostic factor (multivariate hazard ratio 2.425; 95% confidence interval, 1.205–4.878; $P=0.013$; Table 2).




Figure 2 Kaplan–Meier curves according to the miR-223 and FBXW7 status. **(A)** The overall survival curves are presented according to the expression level of miR-223 in ESCC patients. Patients with high miR-223 expression had a poorer prognosis than those with low expression (log-rank (Mantel–Cox) test; $P=0.034$). **(B)** The overall survival curves according to the FBXW7 expression level in ESCC patients. The negative FBXW7 group had a significantly poorer prognosis for 5-year overall survival than the positive group ($P=0.023$).

The clinicopathological significance of FBXW7

We used the H score to evaluate the FBXW7 expression level and defined a final staining score of >50 as positive for FBXW7. Among the 109 ESCC patients, 39 patients (35.8%) showed positive staining for FBXW7. The associations between the patient clinicopathological characteristics and FBXW7 are summarised in Supplementary Table 1. There were no significant differences in the patient clinicopathological characteristics.

The relationship between FBXW7, and c-Myc and c-Jun in ESCC tissues

We examined the association between the FBXW7 protein expression, and c-Myc and c-Jun protein expression levels in the




Figure 3 The relationship between the expression of miR-223, and FBXW7, c-Myc, and c-Jun proteins in ESCC patients. **(A–C)** In the miR-223-low expression cases, the FBXW7 protein was expressed at a high level, whereas the levels of the c-Myc and c-Jun proteins were below the limit of detection in the same tissue sections. **(D–F)** In contrast, in the miR-223-high expression cases, the FBXW7 protein was expressed at a low level, and there was strong expression of the c-Myc and c-Jun proteins. ($\times 200$ original magnification, scale bar: $50\ \mu\text{m}$).

Table 2 The results of univariate and multivariate analyses for overall survival (Cox proportional regression model)

Factors	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age ($64 < /65 >$)	1.559	0.887–2.739	0.123	1.95	1.084–3.506	0.026*
Sex (male/female)	0.622	0.265–1.4682	0.276	—	—	—
T1/2,3	1.386	0.719–2.673	0.33	—	—	—
Tumor size ($40\ \text{mm} < , 40\ \text{mm} \geq$)	1.389	0.791–2.438	0.253	—	—	—
Lymph node metastasis (absent/ present)	2.345	1.254–4.385	0.008*	2.371	1.250–4.499	0.008*
Stage I, II/III, IV	1.947	1.079–3.513	0.027*	—	—	—
Venous invasion (absent/present)	1.66	0.892–3.089	0.11	1.42	0.747–2.699	0.285
Lymphatic invasion (absent/present)	2.978	1.513–5.862	0.002*	—	—	—
FBXW7 expression (positive/negative)	2.106	1.094–4.057	0.023*	—	—	—
miR223 expression (low/high)	2.272	1.099–4.695	0.027*	2.425	1.205–4.878	0.013*

Abbreviations: CI = confidence interval; HR = hazard ratio. * $P < 0.05$.